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Medicine and Surgery, Federico II University. PAbstract Background: The advancement of knowledge in the ﬁeld of regenerative medicine is
increasing the therapeutic expectations of patients and clinicians on cell therapy approaches.
Within these, stem cell therapies are often evoked as a possible therapeutic option for diabetes,
already ongoing or possible in the near future.
Aim: The purpose of this document is to make a point of the situation on existing knowledge and
therapies with stem cells to treat patients with diabetes by focusing on some of the aspects that
most frequently raise curiosity and discussion in clinical practice and in the interaction with the
patient. In fact, at present there are no clinically approved treatments based on the use of stem
cells for the treatment of diabetes, but several therapeutic approaches have already been evalu-
ated or are being evaluated in clinical trials.
Data synthesis: It is possible to identify three large potential application ﬁelds: 1) the reconstruc-
tion of the b cell mass; 2) the immunomodulation in type 1 diabetes (T1D); 3) the treatment of
complications. In this study we will limit the discussion to approaches that have the potential for
clinical translation, deliberately omitting aspects of basic biology and preclinical data. Also, we
intentionally omit the treatment of the complications that will be the subject of a future docu-
ment. Finally, an overview of the Italian situation regarding the storage of cord blood cells for the
therapy of diabetes will be given.
ª 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.Introduction
There are currently no proven treatments for diabetes
using stem cells. Nevertheless, a signiﬁcant amount ofiva in ambito diabetologico”.
r.it (L. Piemonti).
ordi V, et al., Stem cells to restor
://dx.doi.org/10.1016/j.numecd.20
logy, the Italian Society for the Study of A
ublished by Elsevier B.V. All rights reserveexperiences report the potential of stem cells to contribute
to diabetes therapy. Pluripotent and multipotent stem cells
deriving from embryos, fetal and adult tissues are under
investigation for potential application in the treatment of
diabetes and its complications. In particular, the ﬁeld of
differentiation of pluripotent stem cells into insulin pro-
ducing cells has made great steps forward and landed in a
clinical trial in patients with diabetes. Moreover, extensive
studies are ongoing regarding the use of bone marrow-e insulin production and cure diabetes, Nutrition, Metabolism &
17.02.004
therosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical
d.
2 V. Sordi et al.and cord blood-derived stem cells for immunomodulation
in diabetes. We here give an overview of the current sit-
uation of these studies on stem cells, focusing on clinical
applications in type 1 and type 2 diabetes.Endogenous cells for b cell replacement
The ﬁrst cell source to be considered for functional
replacement is the endogenous b cell. Unfortunately
endocrine pancreas is a tissue with a very slow turnover of
cells, with a proliferative ratio of 0.1e0.3%/day in 1-year-
old mice [1] and even lower proportions in humans. The
potential use of endogenous endocrine cell as a source of
new b cell for transplantation resides in the intrinsic ca-
pacities of proliferation, neogenesis and trans-
differentiation (Fig. 1).
b cell proliferation. Several studies have shown that b
cells mass is regulated dynamically and the relation be-
tween replication and apoptosis can determine the ﬁnal
mass [2,3]. In human, normal expansion of the b cell mass
occurs during the neonatal period, but fades early in
childhood [4]; in adult, b cell replication results increased
in some physiological or pathological states, such as
pregnancy [5] or an obesity-induced insulin-resistant state
[6]. Thus, the use of external agents to expand b cells
ex vivo for transplantation purpose or to stimulate
endogenous cell proliferation in vivo in order to increase
the b cell mass in diabetic patients may be an attractive
approach for b cells supplementation. In fact, b cell
regeneration has been observed also in T1D patients after
onset [7] or even many years after diagnosis [8,9]. Trans-
fection of many cell cycle regulators like cdks (cyclin
dependent kinases) and cyclins into rodent and humanFigure 1 Mechanisms of b cell expansion: pro
Please cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20islets ex vivo, leads to an increase in the replication rate of
b cells [10,11], but the prolonged expression of these
molecules would increase also the risk of oncogenesis. A
safer option is represented by the addition in culture of
growth factors, such as growth hormone (GH), glucagon-
like peptide-1 (GLP-1) or hepatocyte growth factor
(HGF), but in human the elevated proliferation is associ-
ated with a loss of b cell features, like Pdx-1 or insulin
expression [12]. An in vivo therapy with long-acting GLP-1
analogues (exenatide or liraglutide) has been considered
to have a potential for the stimulation of b cell replication
in diabetic patients after proof-of-concept studies per-
formed in patients treated with GLP-1 [13,14], but long-
term data of the evidence of such increase in patients
have yet to be provided. In the ﬁeld of b cell proliferation, a
gene therapy aimed at the reversible inclusion of genes
capable of immortalizing b cells has been tried as well.
During the past 30 years, a number of b cell lines have
been established in rodent [15,16] and many attempts have
been made to generate human b cell lines from many
pancreatic sources, but insulin production by these cells
was extremely low or limited at few passages [17,18]. In
2011 a human b cell line was established transducing
human fetal pancreases with a lentiviral vector that
expressed SV40LT and human telomerase reverse tran-
scriptase (hTERT). One of the cell lines generated with this
strategy, the EndoC-bH1, was further characterized and
resulted able to secrete insulin in response to glucose
stimulation, was stable at least for 80 passages and
expressed many speciﬁc b cell markers, without any sub-
stantial expression of markers of other pancreatic cell
types [19]. In view of clinical use, new generations of these
cell lines have been recently developed and in particular a
novel human b cell line called EndoC-bH3 that containsliferation, neogenesis, transdifferentiation.
e insulin production and cure diabetes, Nutrition, Metabolism &
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Figure 2 Potential sources of b cell replacement in type 1 diabetes: pluripotent stem cells, immortalized b cell lines and pancreatic islets from
cadaveric donor. iPSC Z induced Pluripotent Stem Cells, ESC Z Embryonic Stem Cells.
Stem cells and diabetes 3ﬂoxed immortalizing transgenes and an integrated
tamoxifen (TAM)-inducible form of CRE recombinase has
been created [20]; such lines can be massively ampliﬁed
and then have the immortalizing transgenes removed by
simple addition of TAM, giving rise to non-proliferating
functional human b-cells. These newly produced cells
potentially represent a preclinical model for cell replace-
ment therapy in diabetes, but further studies are required
to determine their actual safety (see Fig. 2).
b cell neogenesis. Another completely different point of
view is the theory that neogenesis is the mechanism
responsible for b cell mass expansion in conditions like
pregnancy or obesity. An autopsy study on human pan-
creata during or after pregnancy supports this hypothesis:
Butler et al. observed the presence of more new small is-
lets rather than an increase in b cell replication, islet size
or change in apoptosis [21] (Butler et al., 2010). They also
observed an increased number of insulin positive cells
within ducts, indicating that duct cells can differentiate in
b cells in certain conditions or that pancreatic stem/pro-
genitor cells are localized in pancreatic ducts. Experiments
of 90% pancreatectomy in rats show the substantial
regenerative capacity of the adult pancreas [22] and in a
recent work it was demonstrated that this regeneration
follows a dedifferentiationeredifferentiation paradigm, in
which mature duct cells dedifferentiate to a progenitor-
like state and then differentiate to form all pancreaticPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20cell types, including b cells [23]. Also in this work an
increased proliferation rate of the remaining b cells was
observed, indicating that replication and neogenesis are
not mutually exclusive and they both contribute to main-
tain an adequate b cell mass after birth, but there are
important differences in the balance of these two path-
ways depending on species and age [24].
Transdifferentiation into b cell. The potential of a cells as
possible source of insulin-producing cells has also been
explored, since these cells are preserved in diabetic pa-
tients [25] and are the most abundant endocrine cells in
islets other than b cells. Collombat et al. [26] have shown
that the ectopic expression of Pax4 could force mature a
cell conversion to b cells, reversing chemically-induced
diabetes in mice. In addition, Thorel et al. [27]
conﬁrmed the differentiation potential of a cells report-
ing their spontaneous conversion to new functional b cells
using a selective diphtheria toxin-mediated b cells abla-
tion model. Recently it was shown that GABA and the
antimalarial drug artemether, which act on GABAergic
pathways, can drive pancreatic cells with an a-cell
phenotype toward a b-cell-like phenotype. As reported in
two papers [28,29], these drugs can stimulate the pro-
duction of sufﬁcient numbers of new b-like cells to
reverse severe diabetes in mice. These data suggest a
therapeutic potential of GABA pathways to restore the b
cell mass in diabetes.e insulin production and cure diabetes, Nutrition, Metabolism &
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Several publications have reported the ability to differen-
tiate or transdifferentiate into insulin producing cells of
stem cells of different origin or precursors isolated from
pancreas or other tissues. For many of these approaches,
the results have not been conﬁrmed in other laboratories
or in clinical studies and are therefore controversial. At the
moment the only consistent results in terms of quantity
and quality are those achieved with the use of pluripotent
stem cells (embryonic stem cells or pluripotent stem cells
obtained by the reprogramming of somatic cells) (see
Fig. 2). As short-term clinical perspectives, the most
advanced approach (as clinical phase 1e2 study already
started) refers to the possibility of using pancreatic pro-
genitor cells derived from pluripotent stem cells implanted
subcutaneously within a macro-device where cells can
differentiate in vivo into insulin-producing cells [30e33].
The “product” in question is called VC-01 [34] and con-
sists of pancreatic progenitor cells (referred to as PEC-01),
derived from an embryonic stem cell line [35] encapsu-
lated in a macro-device called Encaptra. The US Food and
Drug Administration (“FDA”) has approved the Investiga-
tional New Drug Application (“IND”) for the use of VC-01
in the treatment of T1D in August 2014. VC-01 was
developed by ViaCyte, a Californian company supported by
both the California Institute for Regenerative Medicine
(CIRM) and the Juvenile Diabetes Research Foundation
(JDRF). The clinical study (called STEP ONE, “A Safety,
Tolerability, and Efﬁcacy Study of VC-01 Combination
Product in Subjects With Type One Diabetes Mellitus; NCT
02239354, ClinicalTrials.gov) is a prospective, multicenter
open-label study which provides the VC-01 system to
patients with T1D in the absence of immunosuppression,
since the macro-device should be able to protect cells from
the immune response. The study involves the recruitment
of forty subjects and the ﬁrst patient has been transplanted
on October 29, 2014. At the moment there is no informa-
tion on the preliminary results. The study will soon be
replicated in Canada, at the University of Alberta. In the
short-to-medium term it is likely that similar approaches
will also be developed by other research groups, since in
recent years at least two other protocols to differentiate
insulin-producing cells with a seven steps protocol with
high efﬁciency have been described. In fact, researchers at
bLogics Venture, a subsidiary of Johnson & Johnson, in
collaboration with the University of British Columbia,
developed a highly efﬁcient differentiation protocol able to
generate mature insulin-secreting cells in vitro starting
from pluripotent stem cells [36e41]. Similarly, the Harvard
Stem Cell Institute described a third protocol to generate
in vitro insulin secreting mature cells from pluripotent
stem cells with high efﬁciency [42].
Stem cells as feeder or immunomodulatory cells for the
treatment of diabetes
In recent years, the well-established clinical experience in
the ﬁeld of hematology has encouraged the use of stemPlease cite this article in press as: Sordi V, et al., Stem cells to restor
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non-hematological diseases. Several clinical studies have
been initiated for the treatment of type 1 and type 2 dia-
betes, involving hematopoietic stem cells and stromal/
mesenchymal stem cells (MSC) derived from BM and cord
blood (or from the extra-embryonic annexes), thanks to
the availability of simple protocols for the collection,
expansion and storage of these stem cells. Many groups
have studied their potential role in the induction and/or
restoration of tolerance and in the remodeling of pancre-
atic tissue as “feeder” cells while their direct differentia-
tion into insulin-producing cells turned out to be less and
less likely (Fig. 3).
Intra-pancreatic infusion of autologous BM
In the past the possibility for BM cells to differentiate into
cells capable of producing insulin in response to glucose
was suggested [43e45] but such results are extremely
controversial and have not been conﬁrmed by other
studies [46e48]. More recently it was assumed that BM
cells could have a different role, thanks to the evidence
that, in some models of BM transplantation, cells can
initiate regeneration of the endocrine pancreas by stimu-
lating both b cell proliferation and islet neogenesis [49,50].
Based on these assumptions, some clinical trials for
treatment of diabetes have been conducted with unpuri-
ﬁed mononuclear cells derived from autologous BM
infused intra-arterially in the pancreas (see Table 1).
Among these experiences there are those of the hospitals
in India [51,52], Argentina [53], China [54,55] and Spain
[56]. In relation to T1D, the clinical study conducted at the
University Hospital Clinic of Barcelona has reported no
effects on the serum levels of C-peptide (basal and stim-
ulated), no changes in insulin requirements or metabolic
control in the treated patients. Due to lack of efﬁcacy the
study, initially designed to recruit ten subjects, was
stopped after the third patient. In relation to type 2 dia-
betes (T2D), published results are difﬁcult to interpret.
Twenty-ﬁve patients with T2D received autologous
mononuclear BM cells injected through the dorsal artery of
the pancreas in combination with hyperbaric oxygen
treatment in Buenos Aires [53]: all metabolic parameters
measured (blood glucose and fasting c-peptide, HbAlc,
insulin) were better than the baseline in the ﬁrst year of
follow-up. Improved glycemic control and decreased in-
sulin requirements or use of oral hypoglycemic agents
have also been reported in 31 patients with T2D recruited
in China [54] and treated in a similar manner. Moreover,
Hu et al. [55] have described the effectiveness at 3 years of
the administration of autologous mononuclear BM cells, in
comparison with the conventional therapy, in 118 patients
with T2D, reporting a signiﬁcant improvement of the
glucose control and a decrease in insulin requirements or
in the use of oral hypoglycemic drugs in transplanted pa-
tients. A similar experience was also described in India.
Here a study was started involving the use of hemato-
poietic stem cells and, as a site of injection, of the pan-
creaticoduodenal artery, that vascularizes preferentiallye insulin production and cure diabetes, Nutrition, Metabolism &
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Figure 3 Potential sources of stem cells for immunomodulation and tissue remodeling, deriving from bone marrow and cord blood.
EPC Z Endothelial Progenitor Cells, HSC Z Hematopoietic Stem Cells, MSC Z Mesenchymal Stem Cells, PSC Z Pluripotent Stem Cells.
Stem cells and diabetes 5the head of the pancreas and part of the body. Six out of
ten treated patients showed a signiﬁcant reduction in the
need for insulin from baseline (74%, with a patient who
achieved and maintained insulin independence for ﬁfteen
months) [51,52] (see Table 1).
In general the results of these studies are difﬁcult to
interpret: the experimental design is often inadequate and
studies lack a control arm, have a high percentage of drop-
outs and heterogeneous populations with different hypo-
glycemic treatments and poor glycemic control at baseline.
Even when a control group was included in the experi-
mental design [54] the study was not randomized, and
indeed the opportunity to choose the treatment arm has
been left to patients. A beneﬁt, usually transient, is
generally reported, but it is unclear whether the effect is
induced by the best treatment due to the entry in the
clinical trial or to real beneﬁts determined by the infusion
of BM cells. In conclusion, at the present time there is no
clear evidence to support the use of intra-pancreatic
autologous BM cell infusion. According to the Reﬂection
paper on classiﬁcation (http://www.ema.europa.eu/docs/
en_GB/document_library/Scientiﬁc_guideline/2015/06/
WC500187744.pdf) of the Committee for Advanced Ther-
apies (CAT) of European Medicines Agency (EMA), a
product whose active substance is made up of BM mono-
nuclear cells infused in the pancreas intra-arterially with
the aim to restore or modify plasma insulin levels, andPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20thus treat diabetes, has to be classiﬁed as advanced ther-
apy medicinal product (ATMP). Such a medicinal product
must then be considered an investigational medicinal
product and should therefore be offered to patients only
within controlled clinical trials, adequately assessed by the
ethics committee and the competent regulatory
authorities.Transplantation of BM hematopoietic stem cells
Hematopoietic stem cell (HSC) transplantation is now
widely recognized as a curative therapy for many hema-
tologic diseases. Over the past two decades, the trans-
plantation of autologous HSC has also been studied as a
treatment option for patients with severe autoimmune
diseases considered refractory to conventional therapy
[57]. The rationale behind these studies lies in the
conviction that it is possible to replace the defective im-
mune system, which recognizes the self-proteins as anti-
gens, with a healthy immune system, regenerated starting
from autologous HSC in the absence of the accidental
environmental circumstances that led to the development
of the autoimmune response. In clinical routine, the re-
cipients of HSC transplantation are subjected to a powerful
immunosuppressive therapy after HSC mobilization from
the BM to the peripheral blood using different protocolse insulin production and cure diabetes, Nutrition, Metabolism &
17.02.004
Table 1 Studies on transplantation of autologous bone marrow mononuclear cells for the treatment of diabetes present in ClinicalTrial.gov.
ClinicalTrial.gov Place Cells Infusion site Diabetes Status Ref
NCT00821899 Hospital Clinic Universitari, Barcelona,
Spain
BM mononuclear cells Intrapancreatic,
intraarterial
Type 1 Completed [56]
NCT00644241
NCT01065298
Postgraduate Institute of Medical
Education and Research, Pgimer,
Chandigarh, India
BM mononuclear cells Intrapancreatic,
intraarterial
Type 2 Unknown [51,52]
NCT00767260 Fuzhou General Hospital Fuzhou,
Fujian, China
BM mononuclear cells
þ hyperbaric therapy
Intrapancreatic,
intraarterial
Type 2 Active, not
recruiting
e
NCT01677013 Peking University Aerospace Centre
Hospital, Beijing, China
BM mononuclear cells
þ hyperbaric therapy
Intrapancreatic,
intraarterial
Type 2 Active,
recruiting
e
NCT00465478 Qilu Hospital of Shandong University,
China
BM mononuclear cells Intrapancreatic,
intraarterial
Type 1
and 2
Unknown e
NCT00971503 Pontiﬁcia Universidad Catolica de Chile,
Santiago de Chile, Chile
Total BM Intrapancreatic,
intraarterial
Type 1 Suspended e
NCT01143168
NCT01142050
Armed Police General Hospital,
P. R. Beijing, China
BM mononuclear cells
þ cord blood
Intrapancreatic,
intraarterial,
intravenous
systemic
Type 1
and 2
Unknown e
NCT01832441 Chaitanya Hospital, Pune, Maharashtra,
India
BM mononuclear cells Not clearly
stated
? Active,
recruiting
e
NCT01786707 University of Miami, USA BM mononuclear cells þ
hyperbaric therapy
Intrapancreatic,
intraarterial
Type 2 Completed
6 V. Sordi et al.typically based on the use of Granulocyte-Colony Stimu-
lating Factor (G-CSF) and/or cyclophosphamide. Despite
the well-documented clinical success of autologous HSC
transplantation in correcting certain autoimmune diseases
[58], an accurate explanation of the mechanisms of action
of this treatment is still lacking. Clearly, transplantation is
accompanied by a large debulking of the recipient’s im-
mune system with powerful immunosuppressive condi-
tioning protocols such as total body irradiation (TBI),
cyclophosphamide, the use of depleting monoclonal anti-
bodies (anti-CD2, anti-CD52), ﬂudarabine or anti-
thymocyte globulin (ATG); these treatments determine a
strong lymphopenia of long duration associated with
reduced levels of plasma cells capable of producing auto-
antibodies [59] and the use of such lympho-ablative
therapies, even in the absence of hematopoietic cell
transplantation, is able to stop or slow the progression of
autoimmune diseases [60]. Associated with the effect of
non-speciﬁc immunosuppressive induction protocols, it
has been also demonstrated that the transplant of HSC can
restore immune tolerance by modulating regulatory T cells
and reactivating thymic function [61e63]. Unfortunately,
due to the persistence of autoreactive immune cells (T cells
and B memory, long-lived plasma cells), autoimmunity
may recur after an autologous stem cell infusion and
further studies are needed to identify the optimal induc-
tion protocols to achieve stable and lasting remission of
autoimmunity. Allogeneic HSC transplantation is poten-
tially more effective in preventing the recurrence of
autoimmunity. In fact, a moderate conditioning not
involving the complete ablation of autologous HSC, asso-
ciated with an allogeneic hematopoietic cell trans-
plantation, is able to induce a condition called “mixed
hematopoietic chimerism” in which hematopoietic cells ofPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20donor and recipient coexist to form a mixed immune
system. In this condition, T lymphocytes with high afﬁnity
for the autologous proteins can be eliminated by ensuring
the development of a new tolerance towards the self
[64,65]. Being T1D an autoimmune disease, the possibility
of using transplantation of HSC has been evaluated in
recent years. The use of allogeneic BM transplantation to
prevent the development of T1D has been proposed for the
ﬁrst time in 1985 in the NOD mouse model [66] and more
recently the transplantation of allogeneic stem cells and
the development of “mixed hematopoietic chimerism”
have received a lot of attention for the treatment of T1D.
Numerous preclinical studies have demonstrated the efﬁ-
cacy of allogeneic HSC transplantation both in prevention
and in remission of T1D [67e69] but, despite preclinical
results, autologous transplantation was preferred
compared to allogeneic transplantation in early clinical
trials, given the lower risk of severe toxicity. The ﬁrst
attempt to evaluate the safety and efﬁcacy of a non-
myeloablative immunosuppressive regimen followed by
autologous HSC transplant in patients at onset of T1D has
been proposed by Voltarelli et al. in Brazil [70,71]
(ClinicalTrials.gov Identiﬁer: NCT00315133). In this Phase
I/II study, 23 patients aged between 13 and 31 years with
T1D onset within the past six weeks have been subjected
to the mobilization of HSC (and later recovery and cryo-
preservation) with G-CSF and cyclophosphamide. Before
the re-infusion of autologous HSC, patients received an
immunosuppressive conditioning therapy with ATG and
cyclophosphamide. In the following months (mean follow-
up 29.8) 20 out of 23 patients had remission of the disease
and acquired insulin independence. Twelve of these 20
have maintained a state of insulin independence at last
follow-up (mean 31 months, range 15e52 months), whilee insulin production and cure diabetes, Nutrition, Metabolism &
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Stem cells and diabetes 78 had a recurrence of diabetes requiring insulin therapy,
even at low doses (0.1e0.3 IU/kg). It has not been reported
mortality associated with medication, although two pa-
tients developed bilateral nosocomial pneumonia, 3 pa-
tients late endocrine dysfunction, and 9 oligospermia. In
2009e2011 similar ﬁndings were replicated in 8 patients
treated in Poland using the same protocol [72,73]. All pa-
tients achieved insulin independence with a signiﬁcant
improvement in metabolic control (HbA1c from 12.3% to
6.2% at 6 months after autologous transplantation) and
one patient presented recurrence of diabetes at 7 months.
Li et al. [74] reported the results obtained in 13 patients
with the same mobilization and conditioning scheme,
extending the indications within 12 months from onset of
diabetes: 1) in 11 patients out of 13 there has been a sig-
niﬁcant reduction in insulin requirement, 2) in 3 of 11
patients insulin independence was achieved in the 3
months following stem cell transplantation and it was
maintained for 7 months, more than 3 and more than 4
years respectively, 3) normal HbA1c levels were main-
tained in 7 of the 8 patients who achieved a mean follow-
up of 2 years. Furthermore, the same group published a
case report in which it is shown that insulin independence
can be achieved even in patients who have had an onset of
diabetes with ketoacidosis, a condition that had been
excluded from previous trials [75]. In spite of these results,
Gu et al. have shown in a prospective phase 2 study that
autologous HSC may be more effective if the population
didn’t have ketoacidosis at onset [76,77]. More recently,
however, less encouraging data about the effectiveness of
this approach have been published: a Chinese team re-
ported the results of a study designed to evaluate the
safety and efﬁcacy of autologous HSC infusion in compar-
ison with conventional insulin therapy in 42 children
(aged 1.5e12.5 years) at the onset of T1D: 14 patients
underwent transplantation within 3 months from onset
while 28 control patients were treated with insulin ther-
apy in the same period. The reported results of follow-up
(3e5 years) showed that auto-transplantation deter-
mined: 1) insulin independence in 3 of 14 patients for 2, 3
and 11 months, respectively, 2) the absence of episodes of
ketoacidosis, 3) no signiﬁcant differences in insulin re-
quirements and C-peptide values, 4) HbA1c signiﬁcantly
higher than controls. The conclusion of the study is that
there is no real beneﬁt in favor of autologous HSC trans-
plantation [78]. Summarizing these experiences [79]: in
total about sixty-ﬁve patients were treated, 59% achieved
insulin independence within 6 months after trans-
plantation, and 32% have maintained it at the last follow-
up. Also in all the patients a decrease in HbA1c and an
increase in C peptide values were reported. In spite of the
promising results, 52% of patients experienced adverse
events and one death has been reported, highlighting the
difﬁculty to justify a treatment so potentially dangerous at
diabetes onset. Some clinical studies based on this
approach are still active or pending longer follow-up
(NCT01121029, NCT01285934) and, when published, will
help to complete the picture. At the moment it is difﬁcult
to express a ﬁnal judgment. Also in this case it is necessaryPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20to emphasize that, in spite of the numerous clinical ex-
periences, the majority of the studies did not include a
group of randomized control with traditional insulin
therapy or with only immunosuppression, and when it
was done, it is not evident if a real beneﬁt with the
autologous transplantation of HSC was obtained [78]. Only
the long-term monitoring of patients treated so far can
help to clarify the risk/beneﬁt ratio of this approach in T1D
therapy. It is difﬁcult to imagine that this will be a justi-
ﬁable approach in diabetes, considering morbidity and
mortality associated to autologous hematopoietic stem cell
transplant in the ﬁeld of autoimmune diseases [80e82]
(see Table 2).
Transplantation of BM stromal/mesenchymal stem cells
(MSC)
MSC are another cellular component of the BM and are
essential for maintaining the niche of hematopoietic stem
cells. MSC have been the subject of extensive research for
decades. More than thirty thousand scientiﬁc papers on
these cells have been published in peer reviewed journals
describing their ability to differentiate into multiple cell
lineages, to support hematopoiesis, to exert immune
regulation and to secrete growth factors and cytokines.
This ﬁeld of study has grown especially in the last 20 years
with the discovery of new functionality of these cells
[83e85]. In fact, early MSC were isolated from BM and
classiﬁed as multipotent stem cells only for the mesen-
chymal lineage (bone, fat, cartilage), in a second period
instead these cells began to be isolated from virtually all
postnatal tissues (adipose tissue, Wharton’s jelly, dental
pulp, pancreas, amniotic ﬂuid, liver) and their ability to
differentiate in vitro also along the ectodermal and endo-
dermal lineage was reported. In a third and ﬁnal phase, the
interest in MSC has moved from their plasticity to their
ability to modulate tissue function; a large number of
studies have in fact shown that these cells have immu-
nomodulatory and “feeder” cell functions that are exerted
both by direct cellecell contact or by secretion of cytokines
and/or other soluble factors [86]. The assumption that they
can contribute to the regeneration of tissues by modu-
lating inﬂammation has opened a new interest in their use
as a therapeutic tool to suppress inﬂammation and inhibit
immune responses in graft versus host disease (GVHD), in
Crohn’s disease and in autoimmune diseases such as dia-
betes, multiple sclerosis, rheumatoid arthritis and, as
recently demonstrated, under extremely severe conditions
such as Acute Respiratory Distress Syndrome or ARDS [87].
The immunomodulatory and anti-inﬂammatory properties
are not always constitutively expressed by MSC, but are
rapidly induced by inﬂammatory cytokines such as IFN-g
and TNF-a, a process that occurs both in vitro and in vivo,
and conﬁgures as a requirement for their therapeutic ef-
ﬁcacy [88] (see Table 3).
In relation to the immunomodulatory properties and
potential use of MSC in clinical protocols some key ele-
ments have now been deﬁned, as well reviewed recently
by Wang and [86]. In short:e insulin production and cure diabetes, Nutrition, Metabolism &
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Table 2 Studies on transplantation of autologous hematopoietic stem cells for the treatment of type 1 diabetes present in ClinicalTrial.gov.
ClinicalTrial.gov Place Mobilization Conditioning Diabetes Status Ref
NCT00315133 University of São Paulo, School of
Medicine of Ribeirão Preto, Brasil
cyclophosphamide
(2.0 g/m2), G-CSF
(10 mg/kg/die)
cyclophosphamide
(200 mg/kg),
ATG (4.5 mg/kg).
<6 weeks from
onset
Unknown [70,71]
NCT01341899 Hospital of Nanjing University,
Jiangsu, China
cyclophosphamide
(2.0 g/m2), G-CSF
(10 mg/kg per day)
cyclophosphamide
(200 mg/kg),
ATG (4.5 mg/kg).
<12 weeks from
onset
Active,
recruiting
[74,75]
NCT01121029 Hospital Universitario Dr. José
Eleuterio González; Monterrey,
Nuevo Leon, Mexico
cyclophosphamide
(1.5 g/m2), G-CSF
(10 mg/kg per day)
cyclophosphamide
(500 mg/kg);
ﬂudarabine (30 mg/m2)
<4 weeks from
onset
Completed e
NCT00807651 Shanghai Jiao Tong University
School of Medicine, Shanghai,
China
cyclophosphamide
(2.0 g/m2), G-CSF
(10 mg/kg per day)
cyclophosphamide
(200 mg/kg),
ATG (4.5 mg/kg).
<6 months from
onset
Active, not
recruiting
[76,77]
NCT01285934 Northwestern University,
Chicago, Illinois, United States
cyclophosphamide
(2.0 g/m2), G-CSF
(10 mg/kg per day)
cyclophosphamide
(200 mg/kg),
ATG (4.5 mg/kg),
rituxan (500 mg)
<5 months from
onset
Active,
recruiting
e
Table 3 Studies on transplantation of mesenchymal stromal/stem cells for the treatment of diabetes present in ClinicalTrial.gov.
ClinicalTrial.gov Place Mechanism Cells Infusion site Diabetes Status Ref
NCT01068951 Uppsala University Hospital,
Sweden
Immunomodulation Autologous, from BM Systemic infusion Type 1,
onset
Completed [113]
NCT02057211 Uppsala University Hospital,
Sweden
Immunomodulation Autologous, from BM Systemic infusion Type 1,
onset
Recruited [113]
NCT00690066 Mesoblast International Srl in
partnership con JDRF
Immunomodulation Mesenchymal stem
cell line, from BM
(Prochymal)
Systemic infusion Type 1,
onset
Completed e
NCT01322789 University of São Paulo, School
of Medicine of Ribeirão Preto,
Brasile
Immunomodulation Allogeneic, from
BM of ﬁrst-degree
relative
Systemic infusion Type 1,
onset
Recruiting e
NCT01219465 Qingdao University, Qingdao,
Cina
Immunomodulation Alogeneic, from
umbilical cord blood
Systemic infusion Type 1,
onset
Unknown e
NCT01157403 Hospital of the Third Military
Medical University, Chongqing,
China
Immunomodulation Autologous, from BM Systemic infusion Type 1,
onset
Unknown e
NCT01374854 Fuzhou General Hospital
Fuzhou, Fujian, China
Tissue repair Alogeneic, from
umbilical cord blood
Intrapancreatic,
intraarterial
Type 1 Unknown e
NCT01496339 First Afﬁliated Hospital of
Zhejiang University, Hangzhou,
Zhejiang, China
Tissue repair Allogeneic, from
menstrual blood
Intrapancreatic,
intraarterial
Type 1 Unknown e
NCT02302599 Chinese PLA General Hospital,
Beijing, Beijing, China
Tissue repair Alogeneic, from
umbilical cord blood
Systemic infusion Type 2 Recruiting e
NCT01759823 Postgraduate Institute of
Medical Education and
Research, Pgimer, Chandigarh,
India
Tissue repair Autologous, from BM Intrapancreatic,
intraarterial
Type 2 Recruiting e
NCT01576328 Mesoblast International Srl Tissue repair Mesenchymal stem
cell line, from BM
(Prochymal)
Systemic infusion Type 2 Active, not
recruiting
e
NCT01954147 Diabetes Care Center of
Nanjing Military Command,
Fuzhou, Fujian, China
Tissue repair Alogeneic, from
umbilical cord
blood þ liraglutide
Systemic infusion Type 2 Active, not
recruiting
e
NCT01453751 Ageless Institute, Miami,
Florida, United States
Tissue repair Autologous, from
adipose tissue
Intrapancreatic,
intraarterial
systemic
intravenous
Type 2 Recruiting e
NCT01413035 Department of Hematology
of the 2nd Hospital of
Shandong University Jinan,
Shandong, China
Tissue repair Allogeneic, from
umbilical cord
blood and placenta
Systemic infusion Type 2 Unknown e
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Stem cells and diabetes 9 MSC, when injected intravenously, remain mostly
trapped in the lungs, and another signiﬁcant part is the
subject of an immune system attack (instant blood-
mediated inﬂammatory reaction (IBMIR) [89,90] but
some cells, in case of tissue damage, are able to migrate
into the site of injury and participate in the process of
repair [91].
 The percentage of MSC that persist in the homing site is
low and the permanence is generally of short duration,
suggesting a “hit-and-run” effect on damaged tissue
[85].
 In response to inﬂammatory mediators, MSC can pro-
duce a large number of soluble factors (cytokines,
chemokines, growth factors) capable of regulating
inﬂammation and tissue remodeling. Among the factors
that have been described there are: TNF-a, IL-1, IL-6,
IFN-g, TGF-b, HGF, EGF, IGF, FGF, PDGF, KGF,
angiopoietin-1, PGE2, VEGF, SDF-1, IDO, NO and iNOS
[92].
 MSC have the ability to modulate the immune response
either as suppressors or ampliﬁers, depending on the
type and intensity of the signals that they receive from
the microenvironment [93]. Once activated by inﬂam-
matory stimuli, they are able to exert an effect on the
immune system cells in both innate and adaptive re-
action, and, in particular, they are able to suppress the
function of T and B lymphocytes, NK cells, dendritic
cells, macrophages and neutrophils [88].
 In the process of tissue repair MSC are also able to exert
an action on the endogenous cells of the damaged tis-
sue, for example by protecting them from apoptosis or
stimulating their proliferation [94].
However, it remains to be determined what are the
functional tests in vitro that can best predict the thera-
peutic efﬁcacy of MSC as immunomodulatory agents, thus
functioning as release criteria of the cells to be used in the
patient, as well as setting the basis for a comparison of the
results of various clinical protocols based on MSC. In this
regard, a big effort in scientiﬁc societies such as the In-
ternational Society for Cellular Therapy (ISCT) is devoted to
share a platform of functional tests that can quickly lead to
guidelines for therapeutic use of MSC in inﬂammatory and
autoimmune diseases [95,96].
Similarly to the general process of knowledge on MSC,
also for their application in the ﬁeld of diabetes we have
witnessed a ﬁrst phase focused on differentiation into
insulin-producing cells, with the objective of providing an
autologous source of tissue for transplantation, and a
second phase, in which the use of MSC has been ﬁnalized
to tissue remodeling and modulation of the immune
response.
Many attempts have been made to differentiate the
MSC in vitro into cells that produce insulin. Several studies
have reported the appearance of insulin mRNA in cell
cultures treated with deﬁned combinations of growth
factors [97e99]. An example for the many studies made inPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20this area is a published study in which a 18-day differen-
tiation protocol with the use of FGF-b, EGF, activin and b-
cellulin was applied [100]. Differentiated cells formed ag-
gregates, some of which are very similar to pancreatic is-
lets, capable of producing C-peptide. The limits of this and
of many previously published studies are that, on closer
inspection, none of these differentiated cells show the
characteristics necessary to be deﬁned as b cells, in
particular the secretion of insulin in response to glucose
stimuli and the ability to normalize glycemia in diabetic
animal models. Furthermore, in a recent study, some as-
pects of safety were highlighted, because, in experiences in
which MSC have been forcedly converted into another
type of cell, the differentiated cells obtained were able to
decrease glycemia in diabetic mice but also had a tumor-
igenic potential [101]. So far, though aware that the risk of
neoplastic transformation may be even greater, the most
convincing data on the reprogramming of MSC into func-
tional b cells derive from studies that use genetic modiﬁ-
cation. This approach is based primarily on the forced
expression of transcription factors involved in the em-
bryonic development of the pancreas such as Pdx1 and/or
Ngn3 [102e107], but this strategy must be improved in
order to increase its effectiveness before it can generate a
good candidate for b cell replacement in clinical applica-
tions, although it is clear that the risk of tumorigenesis
strongly limits this approach.
The ability of MSC to modulate the immune response
and favor tissue repair has been tested and validated in
several preclinical models of diabetes [108e111]. The ex-
periments in vitro and in animal models, together with the
growing number of data with regard to the clinical appli-
cations of MSC in other diseases [112], have led to the
development of clinical trials in the ﬁeld of diabetes.
Among these clinical studies, to date only one has been
completed and the data have been published [113]. This
study (ClinicalTrials.gov Identiﬁer: NCT01068951) was
performed at the University of Uppsala (Sweden) and was
aimed to evaluate the safety and efﬁcacy of the adminis-
tration of autologous MSC derived from BM in patients
with recent onset of T1D. The starting hypothesis is that an
increase in the number of circulating MSC would provide
immunomodulation, and then would be able to interrupt
the immune process that causes b cell death in T1D.
Twenty patients were randomized to cell infusion or to the
control group. The safety of the treatment has been
demonstrated, since treatment with autologous MSC was
well tolerated and no side effects were observed. The
primary efﬁcacy endpoint was centered, as was shown by
improved secretory response of C-peptide to a mixed meal
test during the ﬁrst year post treatment in patients treated
with MSC compared to controls. These encouraging results
have led to a larger, randomized, double-blind study, with
a longer follow-up, to validate the obtained results. This
new study (ClinicalTrials.gov Identiﬁer: NCT02057211)
is ongoing, even if participant recruitment has recently
been suspended for updated regulations of cell culturee insulin production and cure diabetes, Nutrition, Metabolism &
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10 V. Sordi et al.procedure. Another important clinical study was carried
out by Mesoblast International Srl, in collaboration with
JDRF. This Phase II, multicenter, randomized, double-blind,
placebo-controlled trial (ClinicalTrials.gov Identiﬁer:
NCT00690066) is designed to test the safety and efﬁcacy of
Prochymal, a product consisting of human MSC derived
from BM, in patients with newly diagnosed T1D. The
interim evaluation at one year showed that the systemic
infusion of Prochymal is well tolerated and there were no
differences in rates of adverse events in the treated and
placebo groups. In terms of efﬁcacy, there was no evidence
of beneﬁts with regard to preservation of secretory func-
tion measured as release of C-peptide under stimulus,
although a trend towards fewer hypoglycemic events for
patients treated with Prochymal compared to controls was
highlighted. This study is now completed and a full anal-
ysis of data is expected. Among the other active studies,
the only one who apparently is active and recruiting pa-
tients is ongoing in Brazil (ClinicalTrials.gov Identiﬁer:
NCT01322789) in which the intravenous infusion of
autologous MSC obtained from the BM of ﬁrst-degree
relatives is tested in patients with newly diagnosed T1D.
The potential of MSC to counteract hyperglycemia in
diabetic animals through the release of trophic factors
(able to protect existing b cells, stimulate the generation of
endogenous b cells from pancreatic precursors and reduce
peripheral resistance to insulin) has prompted research on
their use in type 2 and long lasting T1D [114e116]. Many
clinical trials have been initiated, and, among these, data
from a study about the use of Mesenchymal Precursor Cells
(MPC, rexlemestrocel-L) in T2D were recently published
[117]. The study was conducted by Mesoblast
(ClinicalTrials.gov Identiﬁer: NCT01576328), the same
company that has tested Prochymal in T1D, and it is a
randomized, placebo-controlled, dose-escalation study,
which aims to evaluate the safety and tolerability of a
single intravenous infusion of allogeneic MSC in patients
with suboptimal control with metformin. The study
demonstrated the safety and feasibility of the infusion of
allogeneic mesenchymal precursors derived from adult BM
(maximum dose 2  106 cells/kg) and also described a
modest metabolic improvement in terms of HbA1c asso-
ciated with the treatment, although the follow up to 12
weeks and the low number of recruited subjects [91] do
not allow to draw deﬁnitive conclusions. Another inter-
esting experience, still ongoing, is a Chinese study
(ClinicalTrials.gov Identiﬁer: NCT01954147), which is
experiencing a combination therapy of allogeneic MSC
from umbilical cord and liraglutide in patients with T2D.
Other studies, based on analogue rationale, provide sys-
temic or intra-pancreatic infusion of MSC obtained
from various districts including the umbilical cord, the
menstrual blood and the placenta (NCT01759823,
NCT01453751, NCT02302599, NCT01759823), but at the
moment results have not been published. So at the present
time there is no clear evidence to support the use of MSC
as a standard therapy for diabetes although some clinical
evidences have been encouraging. This procedure should
only be proposed in controlled clinical trials and properlyPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20evaluated by the Ethics Committees and the competent
regulatory authority.
Umbilical cord blood and extra-embryonic annexes
The umbilical cord is another possible source of stem cells
with potential of differentiation and immunoregulatory
capacity similar to those obtained from BM. In humans, the
umbilical cord normally contains two umbilical arteries
and a vein, hold within a connective tissue called Whar-
ton’s jelly [118]. Umbilical cord blood consists of the blood
left in the umbilical cord and placenta after childbirth.
After the ﬁrst use of cord blood in 1988 for the treatment
of Fanconi anemia [119], there has been considerable
development of its application as a source of cells for the
treatment of many hematological diseases [120]. In fact,
stem cells derived from cord blood can be easily collected
and cryopreserved for years without signiﬁcant loss of
vitality [121,122]. The umbilical cord contains 60e200 ml
of blood and its collection allows the isolation of about
10  106 cells per ml [123]. Umbilical cord blood is
composed of red blood cells, white blood cells, platelets,
plasma, and it is also rich in multipotent or pluripotent
stem cells that can differentiate into various tissues [124].
Among the isolated stem cells are embryonic stem cells,
endothelial progenitor cells, hematopoietic stem cells and
MSC [125,126]. Embryonic stem cells from the umbilical
cord have recently been described as a population of cells,
characterized by very small dimensions, that express the
embryonic markers Oct4, Nanog and SSEA-4 and are
considered virtually totipotent [127]. The endothelial
precursor cells are CD133þ CD34þ VEGFR2þ and are
considered as the most promising source of stem cells for
integration into vascular structures with the aim of
regenerating the blood vessels [128]. MSC are identiﬁed as
CD44þ CD73þ CD90þ CD105þ cells, with the potential to
differentiate into various cell lineages such as chondro-
genic, adipogenic and osteogenic. These cells can be easily
harvested either from cord blood or from Wharton’s jelly
[118]. Finally, hematopoietic stem cells are the most solidly
known and used. Unlike the hematopoietic stem cells
obtained from adult BM, those obtained from umbilical
cord blood have numerous beneﬁts, including increased
proliferative potential and increased telomere length [125]
(see Table 4).
Besides, because of the immunological immaturity of
this tissue, in case of unrelated umbilical cord transplant,
HLA disparity between donor and recipient is better
tolerated and associated with a lower risk of severe acute
GVHD [126,129,130]. Hematopoietic cells of the cord blood
are now considered the most appropriate cells for trans-
plantation procedures for the treatment of diseases, he-
matological and not, for patients in whom it is not possible
to identify a compatible donor [120,131].
In recent years, the use of cells obtained from the um-
bilical cord for the modulation of the immune system in
autoimmune diseases has acquired great interest
[132e135]. In theory, umbilical cord may have a signiﬁcant
role in the treatment of diabetes because of the variety ofe insulin production and cure diabetes, Nutrition, Metabolism &
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Table 4 Studies on transplantation of cord blood cells for the treatment of diabetes present in ClinicalTrial.gov.
ClinicalTrial.gov Place mechanism cells Infusion site Diabetes status Ref
NCT00305344 University of Florida,
Gainesville, Florida,
United States
Immunomodulation Autologous, from
umbilical cord
blood
Systemic
infusion
Type 1,
onset
Completed [143,144]
NCT00873925 University of Florida,
Gainesville, Florida,
United States
Immunomodulation Autologous, from
umbilical cord
blood þ vitamin
D3 and Omega 3FA
Systemic
infusion
Type 1,
onset
Completed [140]
NCT00989547 Technische Universität
München
Immunomodulation Autologous, from
umbilical cord
blood
Systemic
infusion
Type 1,
onset
Unknown [145]
NCT01996228 The Second Xiangya
Hospital, Changsha,
Hunan, China,
Immunomodulation Allogeneic, from
umbilical cord
blood (Stem Cell
Educator therapy)
Ex vivo “contact”
with autologous
lymphocytes
Type 1 Recruiting [149]
NCT01350219 The Second Xiangya
Hospital, Changsha,
Hunan, China,
Immunomodulation Allogeneic, from
umbilical cord
blood (Stem Cell
Educator therapy)
Ex vivo “contact”
with autologous
lymphocytes
Type 1 Recruiting [149]
NCT01415726 General Hospital of
Jinan Military Command,
Jinan, Shandong, China
Immunomodulation Allogeneic, from
umbilical cord
blood (Stem Cell
Educator therapy)
Ex vivo “contact”
with autologous
lymphocytes
Type 2 Completed [150]
NCT01219465 Qingdao University,
Qingdao, Cina
Immunomodulation Allogeneic, MSC
from cord blood
Systemic
infusion
Type 1,
onset
Unknown
NCT01954147 Diabetes Care Center
of Nanjing Military
Command, Fuzhou,
Fujian, China
Tissue repair Allogeneic, MSC
from cord blood
þ liraglutide
Systemic
infusion
Type 2 Active, not
recruiting
NCT01143168 Armed Police General
Hospital, P. R. Beijing,
China
Tissue repair Allogeneic, MSC
from cord blood
Intrapancreatic
intraarterial,
Type 1 Unknown
NCT02302599 Chinese PLA General
Hospital, Beijing,
Beijing, China
Tissue repair Allogeneic, MSC
from cord blood
Systemic
infusion
Type 2 Recruiting
Stem cells and diabetes 11stem cells available in this tissue; in fact, both the control of
autoimmunity through the induction of chimerism and
immune tolerance, and the opportunity to overcome the
shortage of insulin-producing cells through processes of
differentiation could be exploited using cells from the um-
bilical cord. Some experimental data showed a potential of
the cells obtained from the umbilical cord to be transformed
into b-like cells, as conﬁrmed by the production of insulin
andC-peptide, but their engraftment and survival invivohas
not been tested [136,137] or was unsatisfactory for pro-
ceeding to hypotheses of clinical use in humans [138,139].
The use of cord blood cells for the treatment of T1D in
relation to their immunoregulatory potential seems more
promising. Starting from the evidence that cord blood
contains a large population of immature T regulatory
lymphocytes (CD4þ, CD25þ, FoxP3þ), the possibility to
infuse autologous cryopreserved cord blood cells at onset
of T1D was explored in a clinical trial [140,141]. In fact,
regulatory T cells have the ability to inhibit the inﬂam-
matory response and induce anergy in effector T lym-
phocytes that play a key role in b cell destruction [142]. In
a ﬁrst pilot study, ﬁfteen children (mean age 5.5 years)
newly diagnosed with T1D (mean 4.1 months from onset)
received an infusion of autologous cord blood cells and
metabolic and immunological responses were tracked over
the time. At 6 months after infusion an increase in thePlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20population of regulatory T cells in peripheral blood, in the
absence of signiﬁcant adverse events, was observed
[140,141]. However, one year after the transplant, there
were no observed changes in insulin requirements, C-
peptide levels, level of autoantibodies or number of reg-
ulatory T-lymphocytes, indicating that the procedure is
feasible and safe, but did not show effectiveness [143]. The
same negative results were seen at the end of the study (2
years of observation), leading to the conclusion that a
single infusion of umbilical cord blood in children with
T1D is not effective in reverting or treating the disease
[144], even when the infusion was followed by one year of
supplementation with vitamin D and Omega-3 [140]. One
of the reasons for the failure of these studies could be that
an insufﬁcient number of cells with regenerative or
immunoregulatory capacity was transferred in patients. In
support of this hypothesis is another study, performed in
seven children with newly diagnosed T1D, which has
highlighted, at 6 months after infusion, a correlation be-
tween the number of CD34þ hematopoietic cells in the
cord blood and the residual b cell function, as assessed by
measurement of C-peptide after stimulation [145].
A different approach has been proposed by Zhao et al.,
who have described in vitro and in preclinical models the
immunomodulatory effect of umbilical cord derived stem
cells on allogeneic T lymphocytes [146,147]. Based on thee insulin production and cure diabetes, Nutrition, Metabolism &
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strategy called “Stem Cell Educator therapy”, and applied it
in a clinical study in humans [148]: 15 subjects (mean age
29 years, range 15e41) with an average history of diabetes
of 8 years (range 1e21) were re-infused with autologous
lymphocytes derived from peripheral blood “re-educated”
through contact with allogeneic umbilical cord stem cells.
This therapy has apparently improved C-peptide levels,
reduced HbA1c values and decreased insulin daily
requirement in patients with or without a residual
pancreatic function, leading the authors to conclude that
the approach was able to control the immune response
sufﬁciently to allow regeneration of native b cells [149].
The same approach was followed in a second open-label
Phase I/II trial in 36 patients with T2D of long duration,
showing again that the treated patients achieved a better
metabolic control [150]. The efﬁcacy and safety of this
approach is currently being tested in a phase I/II clinical
trial in children with T1D (ClinicalTrials.gov Identiﬁer:
NCT01996228, NCT01350219). Very recently a new clinical
trial, based on the use of umbilical cord blood for the
prevention of T1D, has started. In this world ﬁrst clinical
trial (CoRD Study, U1111-1139-5067), Australian re-
searchers are investigating the potential to prevent or
delay the onset of T1D in high risk autoantibody-positive
children using autologous cord blood. The ﬁrst cell infu-
sion was performed in January 2017 and follow up will last
for 3 years.
In conclusion, the use of autologous cord blood as a
source of immunomodulatory cells for T1D therapy was
ineffective or still has to be proven. Other approaches that
use allogeneic cord blood cells are currently being tested
and should be assessed with great attention in terms of
efﬁcacy before they can be applied to a greater number of
patients.
Storage of stem cells derived from cord blood and
extraembryonic annexes for the therapy of diabetes
One of the recurring questions in clinical practice, most
frequently by expectant parents with T1D, is if collection
and cryopreservation of cord blood stem cells or other
components of extraembryonic annexes can be useful to
cure their own diabetes or that of the unborn child in case
of development of the disease in the future. At the state of
current knowledge there is no clinical application of cord
blood cells for diabetes that justiﬁes its preservation for
private use by parents with diabetes. The topic of cord
blood, however, deserves a study more in deep in order to
better understand its usefulness and limitations.
Why storage of cord blood?
The clinical use of cord blood is related to its content of
stem cells, and mainly of hematopoietic stem cells. In fact,
the use of hematopoietic stem cells derived from umbilical
cord blood is a well-established therapeutic reality for the
treatment of patients with various blood disorders, such as
leukemia and lymphoma, and non-cancer diseases such asPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20thalassemia, bone marrow aplasia and congenital immune
deﬁciencies in pediatric and adult patients. In Italy the
complete list of such diseases is shown in the Annex to the
Ministerial Decree of November 18th, 2009 “Disposizioni
in materia di conservazione di cellule staminali da
sangue del cordone ombelicale per uso autologo-
dedicato”, updated in 2014.The situation in Italy
Is it allowed to store cord blood?
In Italy, the current legislation allows the collection and
preservation of umbilical cord blood, and the service is
offered by the National Health System (NHS):
 in case of donation for allogeneic use to charitable
purposes;
 dedicated to baby with a disease occurring at the time
of the birth or highlighted in the prenatal period, or for
use in dedicated consanguineous with a disease present
at the time of collection, in case this disease is treatable
with hematopoietic stem cell transplantation;
 dedicated to families at risk of having children with
deﬁned genetic diseases for which there is proven ev-
idence of use of stem cells derived from umbilical cord
blood;
 dedicated to autologous-use in clinical trials, approved
under current regulations, aimed at gathering evidence
of a possible use of cord blood in case of particular
diseases;
while the legislation prohibits:
 conservation for exclusive autologous use, in the
absence of the above conditions;
 the establishment of private banks in the national
territory;
 all forms of advertising related to private banks.
It is however allowed the collection of umbilical cord
blood for personal use and its export in private facilities
outside the Italian territory according to the rules deﬁned
by a speciﬁc legislative act. For more information, consult
the document “Normativa in tema di conservazione e
donazione del sangue cordonale” which gives full infor-
mation about cord blood donation and storage in Italy.
Where can I donate cord blood?
On national territory, umbilical cord blood is stored in
public facilities (Umbilical Cord Blood Banks) and it re-
mains available to transplant centers in case of need. The
list of Umbilical Cord Blood Banks is public and available at
the following link: http://www.centronazionalesangue.it/
pagine/rete-banche-sangue-cordonale. The Italian Na-
tional Blood Centre with the National Transplant Center
work to ensure safety and reliability of the units preserved
to protect the health of the giver and of the receivere insulin production and cure diabetes, Nutrition, Metabolism &
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cordonale#sthash .lkRERMt6.dpuf).
Why the preservation of cord blood for autologous use
only is not allowed?
Cord blood storage for autologous use is not permitted in
Italy, because currently there is no scientiﬁc evidence
regarding its use for personal purposes outside the cases
indicated by current regulations. For more information, see
the Position Paper “Appropriate use of stem cells” and the
Position Statement “Collection and storage of cord blood in
Italy” from the Ministry of Health. Even ADISCO (Italian
Umbilical Cord Blood Donors Association) has produced a
Position Statement about the collection and storage of cord
blood in Italy.
Are there private cell banks for the conservation of
umbilical cord blood?
In Italy the establishment of private banks for the storage
of umbilical cord blood is not allowed, but there is a
network of “brokers” who organize the pickup, transport
and delivery service of the cord blood from Italy to a bank
abroad.
Are there private banks for the conservation of umbilical
cord blood for the treatment of diabetes?
Browsing the web we identiﬁed 32 private bank websites
that promote the preservation of umbilical cord blood in
Italy for “personal” use. These companies have their
registered ofﬁces in the United States, in San Marino, in the
UK, Slovakia, Belgium, Switzerland, Poland, Germany and
Greece, while the physical locations where stem cells are
preserved are scattered around the world. The average cost
for the collection and cryopreservation of cord blood cells
for about 20 years is of 2370 V (with a range between 1570
and 3100 Euros). A review of the information provided on
the websites on the beneﬁts of cryopreservation of cord
blood cells reveals a confusing and potentially misleading
information model. All private banks publish a list of dis-
eases that “could be treated” with the umbilical cord blood
transplantation, including tumors, bone marrow de-
ﬁciencies and genetic disorders. Most of these diseases are
treatable only with an allogeneic umbilical cord cell
transplant, but many commercial banks do not explain the
difference between autologous and allogeneic transplant
with sufﬁcient clarity, implying that the indications for
allogeneic also apply to autologous transplants. Most
commercial banks also list several conditions that could be
treated in the future with cellular therapies which are
currently at an early stage of research. Twenty-eight of the
32 banks considered report on their websites the useful-
ness of cryopreservation of cord blood stem cells for the
cure of diabetes. In most cases, diabetes appears as one of
the diseases that could be cured in the future and for
which there are ongoing clinical trials to determine its
effectiveness. In some cases, the indication of a potentialPlease cite this article in press as: Sordi V, et al., Stem cells to restor
Cardiovascular Diseases (2017), http://dx.doi.org/10.1016/j.numecd.20use of the stored stem cells in the ﬁeld of diabetes is linked
to the description of clinical trials (often with reference to
the NIH website clinicaltrials.gov), or to the publication of
a list of scientiﬁc articles in which the potential of he-
matopoietic stem cells in diabetes has been tested or,
ﬁnally, to expert testimonials. Some banks report direct
experience of transplantation of stem cells cryopreserved
by individuals with type 1 or type 2 diabetes, without
speciﬁc references to registered clinical trials or scientiﬁc
publications.
Conclusion
The evolution of regenerative medicine and the study of
stem cell biology is opening innovative scenarios even in
the therapeutic ﬁeld. Despite this, the treatments covered
in this document cannot be considered clinical standards
and therefore should only be carried out within clinical
studies approved by ethics committees and by competent
regulatory authorities. In order to better inform patients,
the International Society for Stem Cell Research has
compiled the online guide for patients about participation
to clinical trials with cell therapy, translated into many
languages, that can be found at this address: http://www.
closerlookatstemcells.org/patient-resources.
Appendix 1. Scientiﬁc societies providing information
about bone marrow and cord blood cell donation.
International references
- European Group for Blood and Marrow Transplantation
(EBMT; https://www.ebmt.org/Contents/Pages/Default.
aspx)
- International Society for Cell Therapy (ISCT; http://
www.celltherapysociety.org/)
- International Bone Marrow Transplant Registry (IBMTR;
http://www.cibmtr.org/pages/index.aspx)
- Joint Accreditation Committee of ISHAGE and EBMT
(JACIE; http://www.jacie.org/)
- Bone Marrow Donor Worldwide (BMDW; http://www.
bmdw.org/)
- World Marrow Donor Association (WMDA; https://
www.wmda.info/)
- International Society of Blood Transfusion (ISBT; http://
www.isbtweb.org/)
- International NetCord Foundation (NETCORD; http://
www.netcord.org/)
Italian references:
- Gruppo Italiano Trapianto Midollo Osseo (GITMO;
http://www.gitmo.it/),
- Italian Bone Marrow Donor Registry (IBMDR; http://
ibmdr.galliera.it/presentazione)
- Associazione Donatori Midollo Osseo (ADMO; http://
www.admo.it/)
- Società Italiana di Ematologia (SIE; http://www.
siematologia.it/)e insulin production and cure diabetes, Nutrition, Metabolism &
17.02.004
14 V. Sordi et al.- Associazione Italiana diOncoematologia Pediatrica
(AIEOP; http://www.aieop.org/web/index.php)
- Società Italiana di Medicina Trasfusionale e di Immu-
noematologia (SIMTI; http://www.simti.it/)
- Società Italiana di Emaferesi (SIDE; http://www.
emaferesi.it/)References
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